替雷利珠单抗联合NP化疗方案对非小细胞肺癌的治疗效果研究  

Efficacy of Tislelizumab combined with NP chemotherapy regimen in the treatment of non-small cell lung cancer

作　　者：尹建宏 Yin Jian-hong(Department of Oncology,Runan People's Hospital,Zhumadian 463300,Henan,China)

机构地区：[1]汝南县人民医院肿瘤科,河南驻马店463300

出　　处：《四川生理科学杂志》2025年第4期845-848,共4页

摘　　要：目的:分析非小细胞肺癌(Non-small cell lung cancer,NSCLC)患者经替雷利珠单抗联合长春瑞滨+顺铂(Vinorelbine plus cisplatin,NP)化疗方案治疗的效果。方法:选取2023年9月至2024年9月期间在本院就诊的82例NSCLC患者,随机分为对照组和观察组,每组各41例。对照组采用NP化疗方案治疗,顺铂30 mg·m^(-2),静脉滴注,第1~3 d,长春瑞滨25 mg·m^(-2),静脉滴注,第1、8 d;在对照组基础上,观察组采用替雷利珠单抗200 mg·次^(-1),静脉滴注。治疗4周期后,采用酶联免疫吸附法测定肿瘤标志物水平,采用流式细胞仪测定免疫功能指标水平,采用酶免疫分析仪测定血清标记蛋白水平。结果:观察组的临床治疗总有效率显著高于对照组(P<0.05)。与治疗前相比,两组治疗后的糖类抗原125(Carbohydrate antigen 125,CA125)、细胞角蛋白19片段抗原12-1(Cytokeratin 19 fragment antigen 21-1,CYFRA21-1)、神经元特异性烯醇化酶(Neuron-specific enolase,NSE)、癌胚抗原(Carcinoembryonic antigen,CEA)水平均呈下降趋势,且观察组的改善幅度显著大于对照组(P<0.05)。与对照组相比,治疗后观察组的表面抗原分化簇3受体(Cluster of differentiation3^(+),CD3^(+))、表面抗原分化簇4受体(Cluster of differentiation4^(+),CD4^(+))、CD4^(+)/表面抗原分化簇8受体(Cluster of differentiation8^(+),CD8^(+))水平均显著高于对照组(P<0.05)。治疗后,两组的基因Kirsten-Rous肉瘤病毒蛋白(Kirsten rats sarcoma viral oncogene homolog,K-ras)、核苷酸切除修复交叉互补组1(Excision repair cross complementing 1,ERCC1)、高尔基体跨膜糖蛋白73(Golgi protein 73,GP-73)水平均比治疗前显著降低,且观察组的K-ras、ERCC1、GP-73水平降低幅度均显著大于对照组(P<0.05)。两组的毒副反应发生情况无显著差异(P>0.05)。结论:替雷利珠单抗联合NP化疗方案治疗NSCLC,能提高疗效,调节T淋巴细胞亚群,降低血清标记蛋白水平。Objective:To analyze the efficacy of tislelizumab combined with Vinorelbine plus cisplatin(NP)chemotherapy regimen in patients with non-small cell lung cancer(NSCLC).Methods:A total of 82 patients with NSCLC treated in our hospital from September 2023 to September 2024 were selected.Patients were randomly divided into a control group and an observation group,with 41 cases in each group.The control group was treated with an NP chemotherapy regimen,cisplatin 30 mg·m^(-2),intravenously drip,days 1-3,and vincristine 25 mg·m^(-2),intravenously drip,days 1 and 8.On top of the control group,the observation group was treated with tislelizumab 200 mg·dose^(-1),intravenously.After 4 cycles of treatment,the levels of tumor markers were determined by enzyme-linked immunosorbent assay,the levels of immune function indicators were determined by flow cytometry,and the levels of serum marker proteins were determined by enzyme immunoassay analyzer.Results:The total clinical treatment efficacy rate in the observation group was significantly higher than that in the control group(P<0.05).Compared with before treatment,the levels of carbohydrate antigen 125(CA125),cytokeratin 19 fragment antigen 21-1(CYFRA21-1),neuron-specific enolase(NSE),and carcinoembryonic antigen(CEA)in both groups showed a downward trend after treatment,and the improvement in the observation group was significantly greater than that in the control group(P<0.05).Compared with the control group,the levels of cluster of differentiation 3 receptor(CD3^(+)),cluster of differentiation 4 receptor(CD4^(+)),and CD4^(+)/cluster of differentiation 8 receptor(CD8^(+))in the observation group were significantly higher after treatment(P<0.05).After treatment,the levels of kirsten rats arcomaviral oncogene homolog(K-ras),excision repair cross-complementing 1(ERCC1),and Golgi protein 73(GP-73)in both groups were significantly lower than before treatment,and the decrease in K-ras,ERCC1,and GP-73 levels in the observation group was significantly greater than that in the contr

关 键 词：非小细胞肺癌 替雷利珠单抗 化疗方案 

分 类 号：R734.2[医药卫生—肿瘤]